Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
– U.S. launch of maralixibat for Alagille syndrome (ALGS) planned for second half of 2021, if approved by FDA
– Phase 2b programs initiated in Primary Sclerosing Cholangitis, Intrahepatic Cholestasis of Pregnancy and Biliary Atresia
– Financial runw…